Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
IRVINE, Calif., Feb. 19, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief Financial Officer, are scheduled to participate at two investor conferences in February. The first conference is the RBC Capital Markets 2016 Global Healthcare Conference in New York City.
| Event: | RBC Capital Markets 2016 Global Healthcare Conference | ||||||
| Date: | Wednesday February 24, 2016 | ||||||
| Time: | 2:35 pm ET | ||||||
| Participant: | Vaseem Mahboob, Chief Financial Officer |
The second conference is the 2016 BTIG MedTech Conference in Snowbird, Utah. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
| Event: | 2016 BTIG MedTech Conference | ||||||
| Date: | February 24-25, 2016 | ||||||
| Participant: | John McDermott, Chief Executive Officer |
An audio webcast of the Company’s presentation at the RBC Capital Markets 2016 Global Healthcare Conference will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com. The Nellix System is an investigational device in the United States.
COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
